Detection of clinical progression through plasma ctDNA in metastatic melanoma patients: a comparison to radiological progression.

ABSTRACT:

Background

The validity of circulating tumour DNA (ctDNA) as an indicator of disease progression compared to medical imaging in patients with metastatic melanoma requires detailed evaluation.

Methods

Here, we carried out a retrospective ctDNA analysis of 108 plasma samples collected at the time of disease progression. We also analysed a validation cohort of 66 metastatic melanoma patients monitored prospectively after response to systemic therapy.

Results

ctDNA was detected in 62% of patients at the time of disease progression. For 67 patients that responded to treatment, the mean ctDNA level at progressive disease was significantly higher than at the time of response (P < 0.0001). However, only 30 of these 67 (45%) patients had a statistically significant increase in

SUBMITTER: Marsavela G 

PROVIDER: S-EPMC8810871 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature